LOSS OF HETEROZYGOSITY AT THE BRCA1 LOCUS AS A MARKER OF SEN- SITIVITY FOR ADJUVANT CHEMOTHERAPY IN HEREDITARY OVARIAN CANCER


  • A.P. Sokolenko Institute of Oncology, St-Petersburg, Russia
  • A.L. Savanevich Grodno State Medical University, Belarus
  • T.L. Stepuro Grodno State Medical University, Belarus
  • A.V. Shulga Grodno State Medical University, Belarus
  • I.V. Berlev Institute of Oncology, St-Petersburg, Russia
  • E.N. Imyanitov Institute of Oncology, St-Petersburg, Russia
  • N.N. Petrov Institute of Oncology, St-Petersburg, Russia

Abstract

LOSS OF HETEROZYGOSITY AT THE BRCA1 LOCUS AS A MARKER OF SEN- SITIVITY FOR ADJUVANT CHEMOTHERAPY IN HEREDITARY OVARIAN CANCER

References

1. N.V. Mitiushkina, A.G. Iyevleva, A.N. Poltoratskiy, A.O. Ivantsov, A.V. Togo, I.S. Polyakov, et al., Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides, Cancer Cytopathol. 121 (2013) 370-376.



2. A.P. Sokolenko, M.E. Rozanov, N.V. Mitiushkina, N.Y. Sherina, A.G. Iyevleva, E.V. Chekmariova, et al., Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia, Fam. Cancer 6 (2007) 281-286.



3. A.G. Iyevleva, E.N. Suspitsin, K. Kroeze, T.V. Gorodnova, A.P. Sokolenko, K.G. Buslov, et al., Non- founder BRCA1 mutations in Russian breast cancer patients, Cancer Lett. 298 (2010) 258-263.
Published
2017-12-27
How to Cite
Sokolenko, A., Savanevich, A., Stepuro, T., Shulga, A., Berlev, I., Imyanitov, E., & Petrov, N. (2017). LOSS OF HETEROZYGOSITY AT THE BRCA1 LOCUS AS A MARKER OF SEN- SITIVITY FOR ADJUVANT CHEMOTHERAPY IN HEREDITARY OVARIAN CANCER. Biological Markers in Fundamental and Clinical Medicine (scientific Journal), 1(3), 29-31. https://doi.org/10.29256/01.03.2017.escbm10
Section
Selected abstracts